<DOC>
	<DOCNO>NCT00000900</DOCNO>
	<brief_summary>To describe magnitude duration change HIV-1 RNA level acute febrile illness . To identify factor associate increase , i.e. , type illness ultimately diagnose ( bacterial , viral , fungal ) , CD4 cell count , antiretroviral treatment regimen . To describe change phenotypic marker immune activation/dysregulation CD4 CD8 lymphocyte subset relationship intercurrent illness . To describe change plasma cytokine soluble activation marker relationship plasma HIV-1 viremia onset intercurrent illness . To characterize viral biologic phenotype viral drug susceptibility genotype , , onset acute febrile illness . To characterize expression HIV-1 co-receptors , , onset acute febrile illness Repeated episodes intercurrent infection postulate important stimulus progression HIV infection . The study intercurrent illness patient initially undetectable viral load remove viral load possible cause virologic immunologic change allow direct association intercurrent illness change viral load , viral HIV-1 phenotype , viral HIV-1 genotype , T cell phenotype . Studying intercurrent illness viral load provide opportunity characterize potentially dynamic change viral load also phenotypic marker T cell activation , plasma cytokine level , phenotypic genotypic change circulate virus , HIV-1 tropism .</brief_summary>
	<brief_title>The Effects Illnesses HIV Levels Body</brief_title>
	<detailed_description>Repeated episode intercurrent infection postulate important stimulus progression HIV infection . The study intercurrent illness patient initially undetectable viral load remove viral load possible cause virologic immunologic change allow direct association intercurrent illness change viral load , viral HIV-1 phenotype , viral HIV-1 genotype , T cell phenotype . Studying intercurrent illness viral load provide opportunity characterize potentially dynamic change viral load also phenotypic marker T cell activation , plasma cytokine level , phenotypic genotypic change circulate virus , HIV-1 tropism . This study determine whether patient exhibit temporary burst viral replication change response intercurrent febrile illness . Although study treatment , patient study must co-enrolled least 1 ACTG antiretroviral treatment study . Plasma HIV-1 RNA variable measure time presentation , Day 3 , Weeks 1 , 2 , 4 , 8 , 16 , 24 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 infection document license ELISA test kit confirm either Western blot , HIV1 culture , HIV1 antigen , plasma HIV1 RNA second antibody test method ELISA time prior study entry . Undetectable plasma HIV1 RNA ( Roche Amplicor Assay ) within 8 week prior study entry . Documented temperature 101degrees F least 1 2 day prior day screen present day screening , document temperature 101 F day screen fever 1 2 day prior screen . [ AS PER AMENDMENT 7/7/98 : Documented temperature 101degrees F day screen . ] Coenrollment least 1 ACTG antiretroviral treatment study ( NOTE : Coenrollment approve encourage follow ACTG study : 343 , 347 , 359 , 368 , 370 , 372 ) . [ AS PER AMENDMENT 7/7/98 : Must enrol either ACTG antiretroviral therapy study pharmaceutical companysponsored antiretroviral therapy study prior entry . Coenrolled nonACTG pharmaceutical companybased study must baseline viral isolate accessible use study . ] Written inform consent parent guardian 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Interruption current antiretroviral therapy due onset acute intercurrent illness . Concurrent Medication : Excluded : Patients receive IL2 . Patients follow prior condition exclude : Change antiretroviral therapy combination within 8 week prior study entry . Required : Concurrent enrollment ACTG antiretroviral therapy study [ , AS PER AMENDMENT 7/7/98 , nonACTG pharmaceutical companysponsored antiretroviral treatment study ] . Stable antiretroviral and/or nucleoside analog therapy 8 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Polymerase Chain Reaction</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Fever</keyword>
	<keyword>Viral Load</keyword>
</DOC>